Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having ?-folate receptor (FR?) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.

Abstract: The invention provides a kit for detecting the presence or absence of mutations in the selected regions of the target genes associated with colorectal cancer, comprising XNA clamps and primers; wherein the XNA clamps are capable of hybridizing with the selected regions having wild-type sequences in the target genes, and the primers are capable of amplifying the selected regions containing each of the mutations in the target genes. The invention also discloses a method of detecting a mutant gene associated with colorectal cancer, comprising: providing a sample containing DNA and a xeno nucleic acid clamp capable of hybridizing to a wild-type gene; and detecting a mutant of the gene in the sample with a xeno nucleic acid probe capable of hybridizing to the mutant gene.

Abstract: The disclosed tamper-evident closure (100) encloses a medical access device, such as a vascular access device (200), such that it will be visibly apparent if the medical access device contained in the tamper-evident closure becomes exposed. The tamper-evident closure cannot be reapplied over the medical access device in a way to look the same as it did prior to exposing the medical access device. The tamper-evident closures comprise a holding cavity (110), a securing mechanism (160), and an apparent release. The disclosed tamper-evident closures are well suited for securing a medical access device that has an access point for delivering fluid to a patient or removing fluid from a patient.

Abstract: An integrally formed bucket and external organizer is provided. A bucket is provided having a tubular sidewall with an open upper end and a closed bottom end. An integrally formed brim connects to an outside surface of the tubular sidewall proximate to the open upper end. The brim extends radially outward from the tubular sidewall to an external or exterior edge. The brim includes a plurality of apertures that extend though its surface (e.g., between an interior edge attached to the tubular sidewall and the exterior edge). Such apertures may support various items (e.g., tools, fishing gear, etc.).

Abstract: The present disclosure provides modified immune cells or precursors thereof (e.g., modified T cells) comprising a chimeric antigen receptor (CAR) having affinity for Mullerian inhibiting substance type 2 receptor (MISIIR). Compositions and methods of treatment of ovarian and other gynecologic cancers are also provided.

Abstract: One or more memory systems, architectural structures, and/or methods of storing information in memory devices is disclosed to improve the data bandwidth and or to reduce the load on the communications links in a memory system. The system may include one or more memory devices, one or more memory control circuits and one or more data buffer circuits. In one embodiment, the Host only transmits data over its communications link with the data buffer circuit. In one aspect, the memory control circuit does not send a control signal to the data buffer circuits. In one aspect, the memory control circuit and the data buffer circuits each maintain a separate state machine-driven address pointer or local address sequencer, which contains the same tags in the same sequence. In another aspect, a resynchronization method is disclosed.

Abstract: A memory controller receives, via a first interface, a first read request requesting a requested data granule. Based on receipt of the first read request, the memory controller transmits, via a second interface, a second read request to initiate access of the requested data granule from a system memory. Based on a determination to schedule accelerated data delivery and receipt by the memory controller of a data scheduling indication that indicates a timing of future delivery of the requested data granule, the memory controller requests, prior to receipt of the requested data granule, permission to transmit the requested data granule on the system interconnect fabric. Based on receipt of the requested data granule at the indicated timing and a grant of the permission to transmit, the memory controller initiates transmission of the requested data granule on the system interconnect fabric and transmits an error indication for the requested data granule.

Abstract: The present invention relates to compositions and methods for the treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor. One aspect includes a modified canine T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity in canine.

Abstract: The present invention relates to compositions and methods for treating HER2/Neu (ERBB2) expressing cancer cells. In some embodiments, the invention includes an isolated T cell receptor (TCR) having high affinity for and that specifically binds ERBB2369-377 epitope on a target cell. Other embodiments include a T cell or a population of T cells modified to express ERBB2-specific TCR. Further embodiments include methods of using ERBB2-specific TCR gene transfer for treating ERBB2 expressing cancer cells. Also included are methods and pharmaceutical compositions comprising the modified T cells for adoptive therapy.

Abstract: The present invention relates to methods of increasing proliferation and/or programming differentiation status of T cells comprising genetically modifying the cells to inducibly express FOXO1-3A or TCF7 when activated. Also provided are engineered cells modified to inducibly express FOXO1-3A or TCF7 when activated; and methods of treating disease using the engineered cells. Also provided are methods of screening and identifying receptors that specifically bind an antigen or antigens that specifically bind a receptor.

Abstract: The use of genes or biomarkers to more accurately diagnose aggressive prostate cancer in men of African descent or European descent is provided. More specifically, the genes or biomarkers of the present invention can be used in diagnostic tests and methods to determine, qualify, and/or assess aggressive prostate cancer or status, for example, to diagnose or identify aggressive prostate cancer, in an individual, subject, or patient, such as men of African descent or men of European descent.

Abstract: A speaker system uses multiple sound chambers having phi ratios to create a dampening effect to filter out incoherent sounds, thus creating an enhanced listening experience that feels very natural to the listener. The speaker system has at least a sound driver, a first sound chamber having a first volume, and a second sound chamber having a second volume that is approximately 1.6 times the first volume. The speaker system can also have a second sound driver, and a third sound chamber having a third volume that is that is approximately 1.6 times the second volume.

Abstract: Multilayer films comprise polypeptide epitopes from Plasmodium falciparum, specifically a circumsporozoite CIS43 epitope and one or more of circumsporozoite T1, B or T* epitope. The multilayer films are capable of eliciting an immune response in a host upon administration to the host. The multilayer films can include at least one designed peptide that includes one or more polypeptide epitopes from a Plasmodium protozoan.

Abstract: The invention provides compositions and methods for treating cancer by using immune effector cells (e.g., T cells, NK cells) engineered to conditionally express an agent which enhances the immune effector response of an immune effector cell that expresses a Chimeric Antigen Receptor (CAR). The conditional agents described herein include agents that target a cancer associated antigen, e.g., a CAR, agents that inhibit one or more checkpoint inhibitors of the immune response, and a cytokine.

Abstract: The invention provides specific synthetic chimeric xenonucleic acid guide RNA; s(XNA-gRNA) for enhancing crispr mediated genome editing efficiency. The invention also provides methods and compositions for inducing CRISPR/Cas-based gene editing/regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using single guide RNAs (sgRNAs) that have been chemically modified with xeno nucleic acids which enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a sgRNA that has been chemically modified with xeno nucleic acids to correct a mutation in a target gene associated with the genetic disease.

Abstract: The present invention includes compositions and methods for treating T cell lymphomas and leukemias. In certain aspects, the compositions and methods include CAR T cells targeting CD2, CD5, or CD7 and modified cells wherein CD2, CD5, or CD7 has been knocked-out.

Abstract: A system and associated processes may perform a memory access operation that includes receiving a data packet comprising a command of a type of a plurality of types of commands. The processes may include initiating a decoding of a first portion of the command, and automatically speculating as to the type of the command. Based on the speculation as to the type of the command, a bank activate command may be generated before the data packet is entirely decoded or received.

Abstract: An earbud device having a user interface that incorporates a rotary switch is described. The rotary switch is part of a stem that extends from the main body of the earbud, and can provide file selection and/or volume control functions. The interface can include a pressure switch, which can provide switching between on, off, and sleep modes. The pressure switch can also be positioned on the stem, and in some embodiments the rotary switch can also act as the pressure switch when pressed. In some embodiments the user interface can utilize a combination of rotary switch and pressure switch inputs.

Abstract: The invention provides a multiplex method for enriching a plurality of target polynucleotide sequences containing genetic mutations associated with lung cancer comprising: (a) providing a biological sample; (b) isolating DNA from said sample; said DNA including said plurality of target polynucleotide sequences containing genetic mutations; (c) providing a plurality of primer probes targeted to said target polynucleotide sequences said primer probes allowing formation of a PCR product; (d) providing a plurality of target specific xenonucleic acid clamps oligomer probes specific for wildtype polynucleotide sequences; so that during the qPCR process only mutant templates are amplified: (e) admixing the plurality of primer probes and the plurality of xenonucleic clamping probes with the target nucleic acid sample; (f) performing a PCR amplification process in reaction solution under hybridization conditions thereby generating multiple amplicons; and (g) detecting said amplicons and wherein said xenonucleic acid c